Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice

Journal of Clinical Investigation

Volumn 115, Issue 3, 2005, Pages 599-609

  Matsumura, Shin Ichiro ^a   Iwanaga, Shiro ^a   Mochizuki, Satsuki ^a   Okamoto, Hiroyuki ^b   Ogawa, Satoshi ^a   Okada, Yasunori ^a  

^a KEIO UNIVERSITY   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID DERIVATIVE; FIBRONECTIN; GELATINASE A; GELATINASE INHIBITOR; LAMININ;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; CAUSE OF DEATH; CELL INFILTRATION; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DELETION MUTANT; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HEART INFARCTION; HEART LEFT VENTRICLE; HEART MUSCLE; HEART MUSCLE CELL; HEART RUPTURE; HEART VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; KNOCKOUT MOUSE; LEFT CORONARY ARTERY; MACROPHAGE; MACROPHAGE ACTIVATION; MACROPHAGE MIGRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TRANSTHORACIC ECHOCARDIOGRAPHY; WILD TYPE; ZYMOGRAPHY;

EID: 14644435713     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI22304     Document Type: Article

References (49)

1. Antman, E.M., and Braunwald, E. 2001. Acute myocardial infarction. In Harrison's principles of internal medicine. E. Braunwald, et al., editors. McGraw-Hill. New York, New York, USA. 1386-1399.
2. Przyklenk, K., Connelly, C.M., McLaughlin, R.J., Kloner, R.A., and Apstein, C.S. 1987. Effect of myocyte necrosis on strength, strain, and stiffness of isolated myocardial strips. Am. Heart J. 114:1349-1359.
3. Factor, S.M., Robinson, T.F., Dominitz, R., and Cho, S.H. 1987. Alterations of the myocardial skeletal framework in acute myocardial infarction with and without ventricular rupture. A preliminary report. Am. J. Cardiovasc. Pathol. 1:91-97.
4. Gao, X.M., et al. 2002. Lower risk of postinfarct rupture in mouse heart overexpressing beta 2-adrenergic receptors: importance of collagen content. J. Cardiovasc. Pharmacol. 40:632-640.
5. Ichihara, S., et al. 2002. Targeted deletion of angiotensin II type 2 receptor caused cardiac rupture after acute myocardial infarction. Circulation. 106:2244-2249.
6. Sternlicht, M.D., and Werb, Z. 2001. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17:463-516.
7. Okada, Y. 2001. Proteinases and matrix degradation. In Kelley's textbook of rheumatology. S. Ruddy, E.D. Harris Jr., and C.B. Sledg, editors. W.B. Saunders Company. Philadelphia, Pennsylvania, USA. 55-72.
8. Creemers, E.E., Cleutjens, J.P., Smits, J.F., and Daemen, M.J. 2001. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ. Res. 89:201-210.
9. Cleutjens, J.P., Kandala, J.C., Guarda, E., Guntaka, R.V., and Weber, K.T. 1995. Regulation of collagen degradation in the rat myocardium after infarction. J. Mol. Cell. Cardiol. 27:1281-1292.
10. Tyagi, S.C., et al. 1996. Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J. Mol. Cell. Cardiol. 28:1415-1428.
11. Danielsen, C.C., Wiggers, H., and Andersen, H.R. 1998. Increased amounts of collagenase and gelatinase in porcine myocardium following ischemia and reperfusion. J. Mol. Cell. Cardiol. 30:1431-1442.
12. Rohde, L.E., et al. 1999. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 99:3063-3070.
13. Spinale, F.G., et al. 1998. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ. Res. 82:482-495.
14. Hayashidani, S., et al. 2003. Targeted deletion of matrix metalloproteinase-2 attenuates early left ventricular rupture and late remodeling after experimental myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 285:H1229-H1235.
15. Heymans, S., et al. 1999. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat. Med. 5:1135-1142.
16. Creemers, E., et al. 2000. Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. Am. J. Pathol. 156:1865-1873.
17. Okada, Y., et al. 1990. Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur. J. Biochem. 194:721-730.
18. Okada, Y., et al. 1992. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J. Biol. Chem. 267:21712-21719.
19. Tarlton, J.F., Vickery, C.J., Leaper, D.J., and Bailey, A.J. 1997. Postsurgical wound progression monitored by temporal changes in the expression of matrix metalloproteinase-9. Br. J. Dermatol. 137:506-516.
20. Kato, T., et al. 2001. Diminished corneal angiogenesis in gelatinase A-deficient mice. FEBS Lett. 508:187-190.
21. Hartlapp, I., et al. 2001. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J. 15:2215-2224.
22. Lindsey, M.L., et al. 2002. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation. 105:753-758.
23. Mukherjee, R., et al. 2003. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 107:618-625.
24. Doherty, D.E., Henson, P.M., and Clark, R.A. 1990. Fibronectin fragments containing the RGDS cell-binding domain mediate monocyte migration into the rabbit lung. A potential mechanism for C5 fragment-induced monocyte lung accumulation. J. Clin. Invest. 86:1065-1075.
25. Clark, R.A., Wikner, N.E., Doherty, D.E., and Norris, D.A. 1988. Cryptic chemotactic activity of fibronectin for human monocytes resides in the 120-kDa fibroblastic cell-binding fragment. J. Biol. Chem. 263:12115-12123.
26. Mecham, R.P., Hinek, A., Griffin, G.L., Senior, R.M., and Liotta, L.A. 1989. The elastin receptor shows structural and functional similarities to the 67-kDa tumor cell laminin receptor. J. Biol. Chem. 264:16652-16657.
27. Senior, R.M., et al. 1984. Val-Gly-Val-Ala-Pro-Gly, a repeating peptide in elastin, is chemotactic for fibroblasts and monocytes. J. Cell Biol. 99:870-874.
28. Trial, J., et al. 1999. Fibronectin fragments modulate monocyte VLA-5 expression and monocyte migration. J. Clin. Invest. 104:419-430.
29. Sarret, Y., Stamm, C., Jullien, D., and Schmitt, D. 1992. Keratinocyte migration is partially supported by the cell-binding domain of fibronectin and is RGDS-dependent. J. Invest. Dermatol. 99:656-659.
30. Faury, G. 1998. Role of the elastin-laminin receptor in the cardiovascular system. Pathol. Biol. 46:517-526.
31. Schoen, F.J. 1999. The heart. In Pathologic basis of disease. R.S. Cotran, V. Kumar, and T. Collins, editors. W.B. Saunders Company. Philadelphia, Pennsylvania, USA. 543-599.
32. Itoh, T., et al. 2002. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J. Immunol. 169:2643-2647.
33. Nakamura, H., et al. 1999. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res. 59:467-473.
34. Yamanaka, H., et al. 2000. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in rheumatoid synovium. Lab. Invest. 80:677-687.
35. Pasula, R., Wisniowski, P., and Martin, W.J., 2nd. 2002. Fibronectin facilitates Mycobacterium tuberculosis attachment to murine alveolar macrophages. Infect. Immun. 70:1287-1292.
36. D'Armiento, J. 2002. Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction. Trends Cardiovasc. Med. 12:97-101.
37. Senior, R.M., Griffin, G.L., and Mecham, R.P. 1980. Chemotactic activity of elastin-derived peptides. J. Clin. Invest. 66:859-862.
38. McQuibban, G.A., et al. 2000. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science. 289:1202-1206.
39. Murphy, P.M. 1994. The molecular biology of leukocyte chemoattractant receptors. Annu. Rev. Immunol 12:593-633.
40. Ardini, E., et al. 2002. Identification of a novel function for 67-kDa laminin receptor: increase in laminin degradation rate and release of motility fragments. Cancer Res. 62:1321-1325.
41. Itoh, T., et al. 1997. Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J. Biol. Chem. 272:22389-22392.
42. Oba, K., et al. 2002. Prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI-166. Cancer Lett. 175:45-51.
43. Maekawa, R., et al. 2000. Anti-metastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor. Clin. Exp. Metastasis. 18:61-66.
44. Connelly, C.M., Ngoy, S., Schoen, F.J., and Apstein, C.S. 1992. Biomechanical properties of reperfused transmural myocardial infarcts in rabbits during the first week after infarction. Implications for left ventricular rupture. Circ. Res. 71:401-413.
45. Hashimoto, G., et al. 2002. Matrix metalloproteinases cleave connective tissue growth factor and reac-tivate angiogenic activity of vascular endothelial growth factor 165. J. Biol. Chem. 277:36288-36295.
46. Oron, U., et al. 2001. Low-energy laser irradiation reduces formation of scar tissue after myocardial infarction in rats and dogs. Circulation. 103:296-301.
47. Higuchi, M., et al. 1988. Tumoricidal activity of lymphotoxin (tumor necrosis factor beta) in vivo: its effects on macrophages. J. Biol. Response Mod. 7:619-630.
48. Kamisato, S., Uemura, Y., Takami, N., and Okamoto, K. 1997. Involvement of intracellular cyclic GMP and cyclic GMP-dependent protein kinase in alpha-elastin-induced macrophage chemotaxis. J. Biochem. 121:862-867.
49. Mecham, R.P. 1991. Laminin receptors. Annu. Rev. Cell Biol 7:71-91.